Aurora Granted Canadian Plant Breeders’ Rights for Two Proprietary Cannabis Cultivars
- Aurora Cannabis has been granted Plant Breeders’ Rights in Canada for two proprietary cannabis cultivars, Farm Gas and Driftwood Diesel, developed through its internal breeding program.
- These rights provide Aurora exclusive control to grow, propagate, and sell products made from these cultivars, which were developed at the company's research facility in Comox, British Columbia.
- Farm Gas and Driftwood Diesel are core medical marijuana products used by patients in Canada, Germany, Poland, the UK, and Australia, showcasing consistent performance and strong cultivation results.
- The Canadian Plant Breeders’ Rights complement Aurora’s recent variety protections in Europe, strengthening its global medical cannabis platform and international competitive position.
Canadian grant protects Aurora‑developed genetics bred through the company’s advanced research and breeding program (CNW Group/Aurora Cannabis Inc.)
Aurora Cannabis has been granted Plant Breeders’ Rights in Canada for two proprietary cannabis cultivars developed through the company’s internal breeding program.
The rights cover SOT20R07-007, known as Farm Gas, and SOT20R07-005, known as Driftwood Diesel. Both were developed at Aurora Coast, the company’s research and development facility in Comox, British Columbia.
Plant Breeders’ Rights are a form of intellectual property protection for new and distinct plant varieties. In Canada, they are granted by the Canadian Food Inspection Agency and give breeders exclusive rights to produce and sell protected varieties.
For Aurora, the certification gives the company exclusive rights to grow, propagate and sell finished products made from the two cultivars. The company said the varieties were selected for their unique characteristics, including consistent performance and strong cultivation results.
Farm Gas and Driftwood Diesel are currently used as core medical marijuana products for patients in Germany, Poland, the United Kingdom, Canada and Australia.
“These plant breeders’ rights recognize the depth of work behind our leading breeding, genetic development and testing program,” said Lana Culley, vice president of innovation and international operations at Aurora. “They reflect a disciplined, science-driven approach to developing cultivars that deliver consistency, performance and reliability for medical cannabis patients around the world.”
Aurora said the protections strengthen its global medical marijuana platform and support continued research into proprietary genetics. The company also noted that the Canadian rights follow recent variety protection grants in Europe, which it says enhances its competitive position internationally.
The company, traded on the Nasdaq and Toronto Stock Exchange under the symbol ACB, serves medical and consumer marijuana markets in Canada, Europe, Australia and New Zealand.